Gilead, Allergan, Novo and Valeant chiefs make the list of world's top 10

Gilead CEO John Martin

Pharma CEOs are doing a pretty good job at the helm--at least where the Harvard Business Review is concerned. Four of them--Gilead Sciences' ($GILD) John Martin, Allergan's ($AGN) David Pyott, Novo Nordisk's ($NVO) Lars Rebien Sorensen and Valeant Pharmaceuticals' ($VRX) J. Michael Pearson--made the publication's top 10, ranked by their market cap growth and shareholder returns. More

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.